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Endothelin-1 (ET-1), a member of a family of 21 amino
acid peptides possessing vasoconstrictor properties, is
known to stimulate mesangial cell proliferation. In this
study, ET-1 (100 nM) induced a rapid activation of p21ras
in human glomerular mesangial cells (HMC). Inhibition
of Src family tyrosine kinase activation with [4-Amino-
5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimi-
dine] or chelation of intracellular free calcium with 1,2-
bis(2-aminophenoxy)ethane-N,N,N*,N*-tetraacetic acid
acetoxymethyl ester significantly decreased ET-1de-
pendent p21ras activation and suggested the involve-
ment of the cytoplasmic proline-rich tyrosine kinase
Pyk2. We have observed that Pyk2 was expressed in
HMC and was tyrosine-phosphorylated within 5 min of
ET-1 treatment. ET-1-induced activation of Pyk2 was
further confirmed using phospho-specific anti-Pyk2 an-
tibodies. Surprisingly, Src kinase activity was required
upstream of ET-1-induced autophosphorylation of Pyk2.
To determine whether Pyk2 autophosphorylation medi-
ated ET-1-dependent p21ras activation, adenovirus-me-
diated transfer was employed to express a dominant-
negative form of Pyk2 (CRNK). CRNK expression
inhibited ET-1-induced endogenous Pyk2 autophospho-
rylation, but did not abolish ET-1-mediated increases in
GTP-bound p21ras levels. ET-1-induced activation of the
p38 MAPK (but not ERK) pathway was inhibited in HMC
and in rat glomerular mesangial cells expressing the
dominant-negative form of Pyk2. These findings suggest
that the engagement of Pyk2 is important for ET-1-me-
diated p38 MAPK activation and hence the biological
effect of this peptide in mesangial cells.
The proliferation of glomerular mesangial cells is a key event
in the development of proliferative inflammatory renal dis-
eases (1). Endothelin-1 (ET-1)1 is a member of a family of 21
amino acid peptides possessing potent vasoconstrictor proper-
ties whose ability to stimulate mesangial cell proliferation is
well established (2). Moreover, ET-1, acting in concert with
other vasoactive mediators, cytokines, and growth factors,
plays an integral role in the pathogenesis of proliferative glo-
merulonephritis. Stimulation of mesangial cells with ET-1
evokes a wide variety of signaling events (for review, see Ref.
3); however, ET-1-induced cell proliferation occurs primarily
via its activation of the intracellular mitogen-activated protein
kinase (MAPK) extracellular signal-regulated kinase (ERK).
The p38 group of MAPKs has been found to be involved in
inflammation, cell contraction, and cell death (4, 5). Contrac-
tive responsiveness of mesangial cells was shown to depend on
activation of the p38 MAPKs (5, 6) and could perhaps partially
account for ET-1 contractive properties.
On the basis of the genetic and biochemical evidence, it
seems likely that p21ras, a member of the small GTPase super-
family, has a crucial role in growth factor-induced stimulation
of ERK and resultant renal cell proliferation (for review, see
Ref. 7). The active form of p21ras is bound to GTP, whereas the
inactive form is bound to GDP. The exchange of GTP for GDP
is promoted by guanosine nucleotide exchange factors, which
are recruited to the signaling complex by adaptor proteins (for
review, see Ref. 8). Recent findings suggest that ET-1-depend-
ent p21ras activation in mesangial cells requires tyrosine phos-
phorylation of the adaptor protein Shc and the subsequent
formation of the ShczGrb2zSos signaling complex (9). The pre-
cise mechanism by which ET-1 induces Shc phosphorylation
has not been defined. In analogy to p21ras regulation of ERK,
members of the Rho family of small GTPases are positive
regulators of p38 MAPK pathways (10). However, the exact
mechanisms of ET-1 stimulation of p38 MAPKs have not yet
been clarified.
The actions of ET-1 are mediated by ligand-dependent acti-
vation of specific G protein-coupled receptors (GPCRs) (for re-
view, see Ref. 11). GPCRs are devoid of intrinsic tyrosine ki-
nase activity; therefore, the protein tyrosine phosphorylation
induced by ligands of GPCRs depends ultimately upon subse-
quent activation of cellular tyrosine kinases. Evidence suggests
that ET-1 activates members of the Src family of cytoplasmic
tyrosine kinases (12–14). Tyrosine phosphorylation appears to
be essential for the mitogenic effects of many GPCRs ligands,
including ET-1 (3), so it is not surprising that the signaling
pathways linking GPCR activation with mobilization of cellu-
lar tyrosine kinases have become the subject of intensive
investigation.
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One of the typical cellular responses to ligand-dependent
GPCR activation shared by ET-1 is mobilization of intracellular
calcium (for review, see Ref. 15). The cloning of the calcium-
regulated cytoplasmic proline-rich tyrosine kinase Pyk2 (also
known as related adhesion focal tyrosine kinase (RAFTK), focal
adhesion kinase-2 (FAK2), and cell adhesion kinase b (CAKb),
calcium-dependent tyrosine kinase (CADTK)) suggested the
link between GPCRs and the induction of tyrosine phosphoryl-
ation via mobilization of intracellular calcium (16–20). More-
over, a number of studies have supported the role of Pyk2 in
coupling GPCRs with MAPK activation (21, 22). ERK activa-
tion by ET-1 was found to coincide with Pyk2 tyrosine phos-
phorylation in primary astrocytes (13).
Pyk2 and FAK belong to a distinct family of cytoplasmic
protein-tyrosine kinases that are regulated by extracellular
stimuli (23). Although FAK and Pyk2 may have partially re-
dundant roles, they also exhibit distinct differences, notably
with regard to their substrate specificity (24–26). The proline-
rich region of Pyk2 interacts with a number of SH3 (Src homol-
ogy) domain-containing proteins, including the docking protein
Crk-associated substrate (p130cas) (27) and PAP (Pyk2 C ter-
minus-associated protein). Activation of Pyk2, but not FAK,
leads to tyrosine phosphorylation of PAP (26); furthermore,
Pyk2 specifically phosphorylates the carboxyl-terminal cytoso-
lic portion of the potassium channel Kv1.2 (28). Other proteins
reported to associate with Pyk2 include paxillin (29, 30), leu-
paxin (31), Hic-5 (32), and the product of the Ewing sarcoma
gene (EWS) (33).
In this study, we show that glomerular mesangial cells ex-
press significant amounts of Pyk2 and elucidate the role of
calcium-regulated Pyk2 in mediating ET-1-induced signaling
events in these cells. We demonstrate that (i) ET-1-mediated
activation of p21ras depends upon mobilization of intracellular
calcium and activation of Src family of kinases and that (ii)
Pyk2 is tyrosine-phosphorylated in response to ET-1 and that
adenovirus-mediated transfer of a dominant interfering Pyk2
construct abolishes autophosphorylation of endogenous Pyk2,
preventing ET-1-stimulated p38 MAPK activation. ET-1-medi-
ated activation of p21ras and ERK activation were not abolished
by adenovirus-mediated transfer of a dominant interfering
Pyk2 construct. Taken together, these findings suggest that
engagement of the calcium-regulated protein-tyrosine kinase
Pyk2 is important for cellular responses to ET-1 and hence the
biological effects of this peptide.
EXPERIMENTAL PROCEDURES
Materials—Tissue culture media and reagents were from Life Tech-
nologies, Inc. and BioWhittaker, Inc. (Walkersville, MD). Purified hu-
man ET-1, BAPTA/AM, PP2, and PP3 were from Calbiochem-Novabio-
chem. PP1 was from Alexis Corp. (San Diego, CA). ECL reagent was
supplied by Amersham Pharmacia Biotech (Little Chalfont, United
Kingdom). The BCA protein assay kit was from Pierce. Bisindolyl-
maleimide I was from the protein kinase C inhibitor set from Calbio-
chem-Novabiochem. All other reagents were from Sigma.
Antibodies—Mouse monoclonal anti-human Ras (Ha-Ras) and anti-
human Pyk2 antibodies were from Transduction Laboratories (Lexing-
ton, KY). Rabbit polyclonal anti-Grb2, anti-p38 MAPK, and anti-FLAG
antibodies and mouse monoclonal anti-Myc antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti-ERK1/2 antibodies were
raised by immunizing rabbits with synthetic peptides and were de-
scribed previously (34). Phosphorylation state-specific anti-Pyk2 Tyr-
402, Tyr-579, Tyr-580, and Tyr-881 antibodies were from BIOSOURCE
International (Camarillo, CA). Phosphorylation state-specific anti-
ERK1/2 and phosphorylation state-specific anti-p38 MAPK antibodies
were from New England Biolabs, Inc. (Beverly, MA). Horseradish per-
oxidase-conjugated anti-Myc antibodies (clone 9E10) were from Roche
Molecular Biochemicals.
Cells—SV40-transformed human mesangial cells (HMC) were kindly
provided by Jean-Daniel Sraer (INSERM Unite 64, Hopital Tenon,
Paris, France) and cultured in RPMI 1640 medium supplemented with
10% fetal bovine serum, 10 mM HEPES, 2 mM glutamine, 100 units/ml
penicillin, and 100 units/ml streptomycin (35). Primary rat glomerular
mesangial cells (RMC) were cultured in RPMI 1640 medium supple-
mented with 17% fetal bovine serum, 100 units/ml penicillin, 100
units/ml streptomycin, 5 mg/ml each insulin and transferrin, and 5
ng/ml selenite. RMC were used between passages 5 and 24.
Recombinant Adenoviral Vectors and Adenoviral Infection—Recom-
binant adenoviral vectors encoding human wild-type Pyk2 (Ad Pyk2
WT) and the carboxyl terminus of Pyk2 termed CRNK (calcium-depend-
ent tyrosine kinase-related non-kinase) (36) (Ad Pyk2 CRNK) were
constructed from replication-deficient adenovirus type 5 with deletions
in the E1 and E3 genes. The cDNA fragment encoding human CRNK
(starting at 692 amino acid of human Pyk2) containing an N-terminal
FLAG epitope (DYKDDDDK) was originally amplified by polymerase
chain reaction and cloned into the HindIII/XbaI sites of the pAdlox
vector. The starting codon (encoding methionine residue) was added at
the N terminus of this recombinant protein.
Serum-restricted mesangial cells were infected with varying titers of
Ad LacZ in 0.9 ml of RPMI 1640 medium containing 2% bovine serum
albumin; and 1 h later, this was replaced with serum-free culture
medium. Following 24–48 h of infection, cells were washed three times
with phosphate-buffered saline and fixed in phosphate-buffered saline
containing 1% glutaraldehyde and 1 mM MgCl2 for 15 min at room
temperature. Cells were then washed three times with phosphate-
buffered saline and stained with 5 mM K4Fe(CN)6z3H2O, 5 mM
K4Fe(CN)6, 2 mM MgCl2, and 0.2% X-gal in phosphate-buffered saline
for 1–2 h at 37 °C. Infection of serum-restricted HMC with Ad Pyk2 WT
or Ad Pyk2 CRNK was performed at a multiplicity of infection (m.o.i.)
of 70 or 90 plaque-forming units/cell. After 1 h, serum-free medium was
added to the plates, and the cells were maintained for 24–48 h prior to
stimulation.
Activated Ras Affinity Binding Assay—Ligation of a cDNA fragment
encoding the Raf1 p21ras-binding domain (RBD) into the SmaI site of
the pGEX-2T vector generated a GST-RBD fusion protein (Amersham
Pharmacia Biotech) (37). The activated p21ras affinity precipitation
assay was performed exactly as described previously (9).
Immunoprecipitation and Western Blot Analysis—Cell lysis, immu-
noprecipitation of samples standardized for protein content, and West-
ern blotting were performed as described previously (9).
RESULTS
Endothelin-induced Ras Activation in Human Mesangial
Cells Depends on Calcium Mobilization and Activation of Src
Family Kinases—We have described previously the kinetics of
ET-1-stimulated p21ras activation in glomerular mesangial
cells (9). In RMC, ET-1 evokes a biphasic GTP loading of p21ras,
with the first peak of activation occurring at 2–5 min and
resulting in a monophasic activation of ERK1 and ERK2. It is
generally accepted that GTP-bound p21ras is able to interact
with Raf1, leading to activation of the ERK signaling cascade.
We have previously demonstrated that p21ras activation is
mediated by an immediate association of tyrosine-phosphoryl-
ated Shc with the guanosine exchange factor Sos1 via the
adaptor protein Grb2. However, thus far, the identity of the
tyrosine kinase responsible for phosphorylating Shc, leading to
the resultant activation of p21ras, is undetermined. In this
study, p21ras activation was assessed by means of an affinity
binding assay that evaluates the quantity of GTP-bound p21ras
protein able to associate with a GST-RBD fusion protein (see
“Experimental Procedures”). As shown in Fig. 1, ET-1 induced
a rapid activation of p21ras in HMC, with the active form of
p21ras being detected as early as 1.5 min. Preincubation of
HMC with PP1, a selective inhibitor of Src family tyrosine
kinases, significantly decreased p21ras activation. In addition,
chelation of intracellular free calcium with BAPTA/AM also
inhibited ET-1-dependent GTP loading of Ras (Fig. 1). These
data suggest that p21ras is activated by ET-1 via Src family
kinases in a calcium-dependent manner.
We next examined whether PP1 had any effect upon ET-1-
induced activation of ERK1 and ERK2. ET-1 induced transient
activation of ERK1 and ERK2 as detected by phosphorylation
state-specific anti-ERK antibodies; as shown in Fig. 2, data
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obtained by this method are consistent with an ET-1-induced
peak of ERK activation occurring at 4 min. In agreement with
its effect on ET-1-induced p21ras activation, preincubation with
PP1 significantly inhibited ET-1-dependent activation of ERK
(Fig. 2). ET-1-dependent ERK1 and ERK2 activation in HMC
was also sensitive to BAPTA/AM treatment (data not shown).
These results provide evidence that inhibition of Src family
tyrosine kinases decreases ET-1-regulated ERK activation. Al-
though this, in all probability, occurs via inhibition of the
Ras-Raf-MEK-ERK signaling cascade, it must be noted that
activation of ERK can occur through both Ras-dependent and
-independent pathways (for reviews, see Refs. 10 and 38).
Furthermore, activation of p21ras is not necessarily accom-
panied by increases in ERK activity since the negative regula-
tion of MAPK activity by dual-specificity phosphatases has
been established (for review, see Ref. 39). Thus, although acti-
vation of the ERK signaling cascade is a direct consequence of
p21ras activation, intracellular p21ras and ERK activation lev-
els may not necessarily correlate.
Pyk2 Is Expressed in HMC and Is Autophosphorylated in
ET-1-treated Cells—The requirement of intracellular calcium
mobilization and Src family kinase activation for ET-1-induced
p21ras activation suggested the involvement of the proline-rich
tyrosine kinase Pyk2 in this signaling pathway. Pyk2 is a
cytoplasmic tyrosine kinase known to be tightly regulated by
intracellular free calcium levels and to interact with Src tyro-
sine kinases. Pyk2 expression has been reported to be re-
stricted predominately to hematopoietic cells and cells of the
nervous system (40). A number of studies have demonstrated
Pyk2 expression in additional cell types (29, 41–43); therefore,
to determine whether Pyk2 is expressed in HMC and whether
it is activated in response to ET-1, HMC lysates were immu-
noprecipitated with anti-Pyk2 antibodies, followed by Western
blot analysis using anti-phosphotyrosine antibodies and anti-
Pyk2 antibodies (Fig. 3). Our results indicate that Pyk2 is
expressed in HMC and that this protein is tyrosine-phospho-
rylated within 5 min of ET-1 treatment. ET-1-mediated Pyk2
activation was also detected by direct measurement of kinase-
autophosphorylating activity in Pyk2 immunoprecipitates from
HMC treated with ET-1 (data not shown).
To study ET-1-mediated Pyk2 tyrosine phosphorylation in
greater details, we used phospho-specific anti-Pyk2 antibodies,
which recognize phosphorylation of specific tyrosines residues,
viz. Tyr-402, Tyr-579, Tyr-580, and Tyr-881. Phosphorylation
of Tyr-579 and Tyr-580 is required for maximal kinase activity
of Pyk2. Tyr-402 is an autophosphorylation site that can serve
as a target for the Src SH2 domain, and phosphorylated tyro-
sine 881 was shown to interact with the Grb2 SH2 domain (22).
As shown in Fig. 4, Tyr-402, Tyr-580, and Tyr-881 all were
phosphorylated 4 min following ET-1 stimulation. Phosphoryl-
ation of Tyr-579 and Tyr-580 was found to be regulated simi-
larly under all experimental conditions; therefore, data for only
one of latter is shown.
We next investigated which tyrosine residues on Pyk2 re-
quired intracellular calcium mobilization for effective phospho-
rylation. As expected, ET-1-induced phosphorylation of all
Pyk2 tyrosines was significantly attenuated in the presence of
the calcium chelator BAPTA/AM (Fig. 4). The dramatic de-
crease in the extent of tyrosine phosphorylation observed in the
presence of BAPTA/AM provides additional evidence for the
selectivity of the phospho-specific antibodies used in this study
since Pyk2 is unique among tyrosine kinases thus far described
in its calcium-dependent activation. The identity of the band
recognized by phospho-specific anti-Pyk2 antibodies was fur-
ther confirmed by immunoprecipitation of Pyk2 with mono-
clonal anti-Pyk2 antibodies and immunoblotting either with
phospho-specific anti-Pyk2 antibodies or with the same mono-
clonal anti-Pyk2 antibodies (data not shown).
Activation of Src Family Kinases Is Necessary for Signaling
through Pyk2 in HMC—Our finding that Pyk2 Tyr-402 was
autophosphorylated in ET-1-treated HMC raised the possibil-
ity that Pyk2 was associated with the tyrosine kinase c-Src. It
has been shown that, following phosphorylation of a conserved
C-terminal tyrosine residue in Src family protein kinases, the
intramolecular interaction between this residue and the SH2
domain maintains these proteins in an inactive “closed” confor-
mation (for review, see Ref. 40 and 44). Pyk2 and Src are
associated via a reciprocal interaction between the phosphoryl-
ated Tyr-402 of the former and the SH2 domain of the latter.
The formation of this complex disrupts the inhibitory intramo-
FIG. 1. Inhibition of ET-1-mediated p21ras activation by
BAPTA/AM and PP1. Quiescent HMC were preincubated either with
BAPTA/AM (50 mM, 60 min) or with PP1 (50 mM, 10 min) and then
stimulated with ET-1 (100 nM) for the times indicated. GTP-bound
active p21ras was isolated by affinity precipitation with a GST-RBD
fusion protein, followed by immunoblot (IB) analysis with anti-p21ras
antibody (upper panel). The fusion protein was detected by Ponceau S
staining of the nitrocellulose (lower panel). The positions of p21ras and
GST-RBD are indicated. Shown is a representative result; the experi-
ment was repeated four times.
FIG. 2. Inhibition of ET-1-induced ERK activation by PP1. Qui-
escent HMC were preincubated with PP1 (50 mM, 10 min) and then
stimulated with ET-1 (100 nM) for the times indicated. Cell lysates were
analyzed using phospho-specific anti-ERK antibodies. The positions of
ERK1 and ERK2 are indicated. Shown is a representative result; the
experiment was repeated three times. IB, immunoblot.
FIG. 3. Pyk2 is tyrosine-phosphorylated in response to ET-1.
Quiescent HMC were stimulated with ET-1 (100 nM) for the times
indicated. Lysates were immunoprecipitated (IP) with a monoclonal
anti-Pyk2 antibody. Immunoprecipitates were analyzed by SDS-PAGE
and immunoblotted (IB) with anti-phosphotyrosine (anti-p-Tyr; upper
panel) and anti-Pyk2 (lower panel) antibodies. The position of Pyk2 is
indicated. Shown is a representative result; the experiment was re-
peated four times.
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lecular interaction, thereby converting Src into its active form.
We have coprecipitated Src with Pyk2 in ET-1-treated HMC
and have also observed colocalization of Src with Pyk2 in ET-
1-treated HMC by means of confocal microscopy (data not
shown). Surprisingly, preincubation of these cells with PP1 or
PP2 (selective inhibitors of Src family kinases) inhibited ET-1-
induced tyrosine phosphorylation of Pyk2. As shown in Fig. 5,
phosphorylation of Tyr-402 and Tyr-580 on Pyk2 in response to
ET-1 was attenuated by PP2. This observed requirement for
Src activity upstream of Pyk2 tyrosine phosphorylation was
unexpected and indicated that an additional mechanism of Src
activation was involved in ET-1-stimulated HMC.
It is known that activation of protein kinase C by the li-
pophilic second messenger sn-1,2-diacylglycerol contributes to
mitogenic signaling by ET-1 in mesangial cells (45). Protein
kinase C can directly activate c-Src by phosphorylation of
Ser-12 and Ser-44 (46); therefore, we investigated the possibil-
ity that Pyk2 phosphorylation could occur via a protein kinase
C-dependent pathway in ET-1-treated HMC. It was previously
shown that depletion of protein kinase C activity partially
inhibited both the angiotensin II- and platelet-derived growth
factor-induced Pyk2 tyrosine phosphorylation (47). Phorbol es-
ter (phorbol 12-myristate 13-acetate) was found to stimulate
tyrosine phosphorylation of Pyk2 in HMC. Significant tyrosine
phosphorylation of Pyk2 Tyr-402 and Tyr-580 was detected
(Fig. 6). Furthermore, the phorbol 12-myristate 13-acetate-de-
pendent effect was completely abolished by preincubation of
HMC with PP2, but not with PP3, its inactive analog. In addi-
tion, preincubation of HMC with GF 109203X (bisindolylmale-
imide; an inhibitor of protein kinase C) for 1.5 h decreased
ET-1-induced autophosphorylation of Pyk2 as detected by
Western blotting with phosphorylation state-specific anti-Pyk2
antibodies (data not shown). Taken together, these data sug-
gest that both calcium mobilization and stimulation of Src
family kinases (possibly in a protein kinase C-dependent man-
ner) are required for ET-1-mediated Pyk2 activation.
Autophosphorylation of Pyk2 Mediates ET-1-induced Activa-
tion of p38 MAPK, but Not Activation of ERK and p21ras—To
determine whether Pyk2 autophosphorylation plays a role in
p21ras activation by ET-1, we used adenovirus-mediated trans-
fer to express Myc-tagged wild-type Pyk2 (Ad Pyk2 WT) and a
FLAG-tagged dominant-negative form of Pyk2 (Ad Pyk2
CRNK) (Fig. 7A). CRNK represents a potential alternative
spliced product of Pyk2 (24) that is able to inhibit autophos-
phorylation of endogenous Pyk2, but that has no effect upon
tyrosine phosphorylation of FAK (36). A transgenic adenovirus
encoding bacterial b-galactosidase activity (Ad LacZ) was used
to routinely assess the efficiency of adenovirus-mediated gene
transfer into HMC (Fig. 7B). Serum-starved HMC transduced
with Ad Pyk2 WT, Ad Pyk2 CRNK, or Ad LacZ (70 plaque-
forming units/cell) were stimulated with ET-1 for 4 min, lysed,
resolved by SDS-PAGE, and immunoblotted with anti-Myc and
anti-FLAG antibodies (Fig. 7, C and D). As expected, expression
of Myc-tagged Pyk2 was detectable in cells infected with Ad Pyk2
WT, whereas FLAG-tagged Pyk2 CRNK was expressed in Ad
Pyk2 CRNK-infected cells. As assessed by X-gal staining, 90% of
cells in this experiment were infected (Fig. 7B).
To test the effect of wild-type Pyk2 and Pyk2 CRNK overex-
pression upon ET-1-stimulated Pyk2 autophosphorylation, the
lysates of control or ET-1-stimulated (4 min) HMC were re-
solved by SDS-PAGE and immunoblotted with phospho-spe-
cific anti-Pyk2 antibodies. Adenovirus-mediated transfer of
wild-type Pyk2 into HMC resulted in constitutive phosphoryl-
ation of Pyk2 Tyr-402, Tyr-580, and Tyr-881 (Fig. 8). The Pyk2
band detected by phosphorylation state-specific anti-Pyk2 an-
tibodies in lanes corresponding to cells infected with Ad Pyk2
WT contained both endogenous Pyk2 and overexpressed Pyk2.
ET-1 stimulated the phosphorylation of Pyk2 Tyr-402, Tyr-580,
and Tyr-881 in Ad LacZ-infected cells, but did not have any
additional effect on the autophosphorylation status of Pyk2 in
cells infected with Ad Pyk2 WT. These data are consistent with
results obtained with wild-type Pyk2 in other cell systems (36).
HMC infected with Ad Pyk2 CRNK exhibited a lower level of
endogenous Pyk2 autophosphorylation of Tyr-402 and Tyr-580
in response to ET-1. The overexpressed Pyk2 CRNK construct
can be easily distinguished from endogenous Pyk2 due to its
different mobility on SDS-polyacrylamide gel (Fig. 7). Surpris-
ingly, Western blot analysis with phosphorylation state-spe-
cific anti-ERK1/2 antibodies did not reveal a decrease in the
ability of ET-1 to induce ERK phosphorylation (Fig. 8).
FIG. 4. ET-1-induced phosphorylation of Pyk2 Tyr-402, Tyr-
580, and Tyr-881 is inhibited by BAPTA/AM. Quiescent HMC were
preincubated with BAPTA/AM (50 mM, 60 min) and then stimulated
with ET-1 (100 nM, 4 min). Cell lysates were analyzed using phospho-
specific anti-Pyk2 Tyr-402 (pY402; upper panel), Tyr-580 (pY580; middle
panel), and Tyr-881 (pY881; lower panel) antibodies. Shown is a repre-
sentative result; the experiment was repeated four times.
FIG. 5. ET-1-induced phosphorylation of Pyk2 Tyr-402 and
Tyr-580 is inhibited by PP2. Quiescent HMC were preincubated with
PP2 (10 mM, 10 min) and stimulated with ET-1 (100 nM) for the times
indicated (in minutes). Cell lysates were analyzed using phospho-spe-
cific anti-Pyk2 Tyr-402 (pY402; upper panel) and Tyr-580 (pY580; lower
panel) antibodies. Shown is a representative result; the experiment was
repeated twice.
FIG. 6. Phorbol 12-myristate 13-acetate-induced phosphoryla-
tion of Pyk2 Tyr-402 and Tyr-580 is inhibited by PP2. Quiescent
HMC were preincubated with PP2 or PP3 (10 mM, 10 min) and stimu-
lated with phorbol 12-myristate 13-acetate (100 nM) for the times indi-
cated. Cell lysates were analyzed using phospho-specific anti-Pyk2 Tyr-
402 (pY402; upper panel) and Tyr-580 (pY580; middle panel) antibodies
and phospho-specific anti-ERK antibodies (anti-p-Erk; lower panel).
Shown is a representative result; the experiment was repeated twice.
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We next checked whether ET-1-mediated activation of
ERK1/2 would be inhibited when autophosphorylation of en-
dogenous Pyk2 was completely abolished. At an infective ratio
of 90 plaque-forming units/cell, a m.o.i. that, in parallel infec-
tions with Ad LacZ, transduced expression in practically 100%
of serum-starved HMC, Ad Pyk2 CRNK completely blocked
endogenous Pyk2 Tyr-402 autophosphorylation (Fig. 9A). The
adenovirus-mediated transfer of Pyk2 CRNK into 100% of qui-
escent HMC was verified by immunofluorescence using anti-
FLAG antibodies (Fig. 9B). The prevention of endogenous Pyk2
autophosphorylation did not inhibit ET-1-induced activation of
ERK1 and ERK2 (Fig. 9A). The inhibition of endogenous Pyk2
autophosphorylation failed also to decrease ET-1-induced
p21ras activation. In both Ad Pyk2 CRNK- and Ad LacZ-in-
fected cells, ET-1 caused an increase in p21ras activation at 2–4
min after stimulation (Fig. 10). It appeared, however, that
Pyk2 autophosphorylation was important for ET-1-induced ac-
tivation of p38 MAPK since Western blot analysis with phos-
phorylation state-specific anti-p38 MAPK antibodies revealed
diminished p38 MAPK phosphorylation in cells infected with
Ad Pyk2 CRNK (Fig. 9A). It is of note that treatment of HMC
with PP2 (an inhibitor of Src family of kinases) decreased both
ET-1-mediated Pyk2 autophosphorylation and ET-1-induced
p38 MAPK activation (data not shown).
To verify our finding that dominant-negative Pyk2 interferes
with the ability of ET-1 to activate the p38 MAPK signaling
pathway, experiments were repeated in RMC. RMC display a
higher level of dependence upon serum growth factors com-
pared with HMC. The efficiency of adenovirus-mediated trans-
fer of wild-type Pyk2 and the dominant-negative construct
CRNK into RMC is demonstrated in Fig. 11. Western blotting
with phosphorylation state-specific anti-ERK antibodies con-
firmed the inability of CRNK to prevent ET-1-induced ERK
activation (Fig. 11, third panel). The ability of ET-1 to induce
p38 MAPK activation was abolished by adenovirus-mediated
transfer of the dominant-negative CRNK construct as detected
by Western blotting with phosphorylation state-specific anti-
p38 MAPK antibodies (Fig. 12).
DISCUSSION
Our data represent the first demonstration of the involve-
ment of Pyk2 in ET-1 signaling in a non-neuronal cell type.
Furthermore, we provide evidence that expression of the dom-
inant interfering Pyk2 construct results in the inhibition of
ET-1-mediated p38 MAPK activation.
ET-1 is a potent vasoconstrictor and is also a strong mitogen
for a number of different cell types, including vascular smooth
muscle cells, glomerular mesangial cells, and a number of
fibroblast cell lines (2, 48). Activation of the cytoplasmic tyro-
sine kinase Pyk2 is a mechanism by which mobilization of
intracellular calcium is coupled to stimulation of non-receptor
tyrosine kinases in ET-1-treated cells. Since we have deter-
mined that ET-1-induced Pyk2 activation is linked to stimula-
FIG. 7. Adenovirus-mediated transfer of wild-type Pyk2 and
Pyk2 CRNK into HMC. A, schematic representation of wild-type (WT)
Pyk2 and adenoviral constructs encoding wild-type Pyk2 and Pyk2
CRNK used in this study. FAT stands for focal adhesion-targeting
sequence. Quiescent HMC were infected with adenoviral constructs at
a m.o.i. of 70 for 24 h. B, as assessed by X-gal staining, Ad LacZ infected
90% of the cells in this experiment. Lysates from Ad LacZ-, Ad Pyk2
WT-, and Ad Pyk2 CRNK-infected cells, quiescent or stimulated for 4
min with ET-1, were resolved by SDS-PAGE and immunoblotted with
anti-Myc (C) or anti-FLAG (D) antibodies.
FIG. 8. Adenoviral Pyk2 constructs modulate the amount of
Pyk2 phosphorylated on Tyr-402, Tyr-580, and Tyr-881 in HMC
stimulated with ET-1. Quiescent HMC were infected with adenoviral
constructs at a m.o.i. of 70 for 24 h. Lysates from Ad LacZ-, Ad Pyk2
WT-, and Ad Pyk2 CRNK-infected cells, quiescent or stimulated with
ET-1 (100 nM) for 4 min, were resolved by SDS-PAGE and immuno-
blotted with phospho-specific anti-Pyk2 Tyr-402 (pY402; first panel),
Tyr-580 (pY580; second panel), and Tyr-881 (pY881; third panel) antibod-
ies. The nitrocellulose was also probed with phosphorylation state-
specific anti-ERK1/2 antibodies (anti-p-Erk; fourth panel) and with
anti-Grb2 antibodies (fifth panel) to confirm equivalency of loading.
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tion of the p38 MAPK signaling pathway, it is possible that
Pyk2 is one of the principal signaling molecules mediating the
contractive properties of ET-1. It was reported that p38 MAPK
mediates glomerular mesangial cell contraction (5). The ability
of p38 MAPK to regulate cell contraction induced by GPCR
ligands is possibly due to its unique capability to activate in
vivo MAPKAP kinase-2/3 (49), which phosphorylates small
HSP27. Small heat shock proteins are known to modulate
polymerization/depolymerization of F-actin and to be involved
in cell contraction. Thus, p38 MAPK-mediated phosphorylation
of small heat shock proteins provides a potential mechanism of
regulation of mesangial cell contractility (6). A schematic rep-
resentation of the proposed role of Pyk2 in p38 MAPK activa-
tion in mesangial cells is depicted in Fig. 13.
It is generally accepted that the mitogenic properties of ET-1
are achieved via activation of the ERK cascade. We have previ-
ously shown that biphasic activation of p21ras by ET-1 sequen-
tially activates the ERK cascade and phosphatidylinositol 3-ki-
nase (9). The rapid and transient initial activation of p21ras is
dependent upon the formation of the ShczGrb2zSos1 signaling
FIG. 9. Adenovirus-mediated transfer of Pyk2 CRNK inhibits ET-1-induced autophosphorylation of endogenous Pyk2 with
different modulating activity upon ERK and p38 MAPK stimulation. Quiescent HMC were infected with either Ad LacZ or Ad Pyk2 CRNK
at a m.o.i. of 90 for 24 h. A, lysates from Ad LacZ- and Ad Pyk2 CRNK-infected cells stimulated with ET-1 for the indicated periods of time (in
minutes) were equalized for protein, analyzed by SDS-PAGE, and immunoblotted with phospho-specific anti-Pyk2 anti-Tyr-402 antibody (pY401;
first panel). The band shown in the first panel represents the autophosphorylation of endogenous Pyk2, which is inhibited by adenovirus-mediated
delivery of Pyk2 CRNK. Cell lysates were also immunoblotted with phosphorylation state-specific anti-ERK antibody (anti-p-Erk; second panel)
and phosphorylation state-specific p38 MAPK antibodies (anti-p-p38; fourth panel). To demonstrate equal protein loading, the stripped nitrocel-
lulose was reblotted with anti-ERK antibodies (third panel). B, as assessed by immunofluorescence with anti-FLAG antibodies (Ab), Ad Pyk2
CRNK infected 100% of the cells. Shown is a representative result; the experiment was repeated twice.
FIG. 10. Adenovirus-mediated transfer of Pyk2 CRNK does not
interfere with ET-1-induced activation of p21ras. Quiescent HMC
were infected with either Ad LacZ or Ad Pyk2 CRNK at a m.o.i. of 90 for
24 h and then stimulated with ET-1 for the indicated periods of time (in
minutes). GTP-bound active p21ras was isolated by affinity precipitation
with a GST-RBD fusion protein, followed by Western analysis with an
anti-p21ras antibody (upper panel). The fusion protein was detected by
Coomassie Brilliant Blue staining of the polyacrylamide gel (lower
panel). The positions of p21ras and GST-RBD are indicated. Some in-
crease in detected p21ras activity at 4 min in cells infected with Ad Pyk2
CRNK and Ad Pyk2 WT, when compared with Ad LacZ-infected cells,
can be explained by the difference in the amount of GST-RBD fusion
protein used, as shown in the lower panel. The experiment was repeated
two times. FIG. 11. Adenovirus-mediated transfer of wild-type Pyk2 and
Pyk2 CRNK into RMC does not interfere with ET-1-induced
activation of ERK. Lysates from Ad LacZ-, Ad Pyk2 WT-, and Ad Pyk2
CRNK-infected cells, quiescent or stimulated for 4 min with ET-1, were
resolved by SDS-PAGE and immunoblotted with anti-Myc (first panel),
anti-FLAG (second panel), phosphorylation state-specific anti-ERK (an-
ti-p-Erk; third panel), or anti-ERK (fourth panel) antibodies. WT,
wild-type.
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complex and is followed by rapid deactivation of p21ras, as a
direct consequence of Sos1 phosphorylation and its release from
this trimolecular module (9). In this study, we provide evidence
that GTP loading of p21ras in ET-1-treated cells is dependent
upon intracellular calcium mobilization and Src family kinase
activation. Tyrosine phosphorylation of endogenous Pyk2 occurs
within minutes of ET-1 stimulation. Results obtained with selec-
tive inhibitors of Src family kinases PP1 and PP2 indicate that
Pyk2 tyrosine phosphorylation is Src-dependent. However, the
inhibition of Pyk2 autophosphorylation via a dominant interfer-
ing CRNK construct does not abolish either the first phase of
ET-1-induced p21ras activation or activation of ERK within 5 min
of ET-1 treatment of mesangial cells.
The mechanism of p21ras activation by ET-1 remains uncov-
ered. It is not clear which tyrosine kinase phosphorylates Shc
directly and how it is activated in mesangial cells. Persistent
Shc phosphorylation is required for the formation of the
ShczGrb2zSos1 complex, leading to biphasic activation of p21ras
(9). The fact that activation of p21ras in mesangial cells is
dependent upon calcium mobilization argues for the existence
of a calcium-dependent event in Shc phosphorylation. It seems
unlikely that the autophosphorylation of Tyr-402 in Pyk2, re-
sulting in assembly with Src, is this calcium-dependent event.
Our data obtained from the expression of the dominant-nega-
tive construct of Pyk2 argue that autophosphorylation of Pyk2
Tyr-402 is not required for p21ras activation in mesangial cells.
Since the phosphorylation of Pyk2 Tyr-881 by Src (or other
kinases) promotes the direct interaction between Pyk2 and
Grb2 (22), the formation of the Pyk2zGrb2zSos1 signaling com-
plex is possible. However, in ET-1-treated cells, Pyk2 autophos-
phorylation is rapid and transient; therefore, a putative
Pyk2zGrb2zSos1 complex would exist only very briefly and so is
unlikely to be responsible for the second peak of p21ras activa-
tion. It is much more possible that some other calcium-depend-
ent event activates c-Src, resulting in rapid activation of Src
tyrosine kinase activity. Evidence exists that, in non-neuronal
cell types, both Gi- and Gq/11-coupled receptors regulate p21
ras
in a calcium-dependent manner (50), ultimately leading to
MAPK activation. Src family kinases mediate signaling to ERK
from both Gi- and Gq/11-coupled receptors (51) and in cells
treated with GPCR ligands. Src family kinases represent a
point of convergence for signals originating from both focal
adhesion complexes and transactivated receptor tyrosine ki-
nases (52). It is of note that, despite the presence of functional
epidermal growth factor receptors, ET-1-stimulated epidermal
growth factor receptor transactivation was not detected in me-
sangial cells (data not shown). c-Src is known to be able to
phosphorylate Shc, and Shc stays phosphorylated and facili-
tates the biphasic activation of p21ras, leading to the conse-
quent activation of ERK and phosphatidylinositol 3-kinase.
In addition to the interaction between a phosphorylated C-
terminal tyrosine residue and their SH2 domains, the closed
conformation of Src family kinases is maintained by a second
intramolecular association between a proline type II helix re-
gion and their SH3 domains (53). It is conceivable that protein
kinase C-dependent c-Src activation leads to Pyk2 phosphoryl-
ation and a pre-sensitization of this kinase to calcium-depend-
ent activation. In this model, protein kinase C would be respon-
sible for abolishing the SH3-mediated inhibition of c-Src
(possibly via conformational changes that would occur subse-
quent to its phosphorylation of c-Src Ser-12 and Ser-44), and
Pyk2 would be responsible for the further opening of this mol-
ecule by interfering with the SH2-mediated intramolecular
interaction. It is important to note that, in addition to c-Src,
other Src family kinases can signal through Pyk2. For example,
Pyk2 is selectively phosphorylated by Fyn during T cell antigen
receptor signal transduction (54), and we have detected copre-
cipitation of Pyk2 with both c-Src and Fyn (data not shown).
Mesangial cells isolated from mice in which individual Src
kinases have been deleted by homologous recombination would
undoubtedly prove useful in elucidating the putative role of
individual Src kinases in ET-1-mediated Pyk2 signaling.
Under different experimental conditions, Pyk2 has been re-
ported to activate all three major MAPK pathways: ERK (16),
JNK (22, 55–57), and p38 MAPK (58). In addition, Pyk2 is
critical for the JAK-mediated ERK and STAT1 activation by
interferon-g (59). Since we were not able to detect activation of
JNK in glomerular mesangial cells in response to ET-1, we
focused our studies on evaluating the role of Pyk2 in signaling
via ERK and p38 MAPK. It must be taken into consideration
that activation of signaling pathways resulting from overex-
pression of wild-type Pyk2 could be quite different from those
that are mediated by endogenous Pyk2 in response to extracel-
lular stimulus.
The mechanism by which calcium mediates Pyk2 activation
is not known. The fact that, in vitro, Pyk2 is directly activated
FIG. 12. Adenovirus-mediated transfer of Pyk2 CRNK into
RMC interferes with ET-1-induced activation of p38 MAPK. Ly-
sates from Ad LacZ- and Ad Pyk2 CRNK-infected cells, quiescent or
stimulated for the indicated periods of time (in minutes) with ET-1,
were resolved by SDS-PAGE and immunoblotted with phosphorylation
state-specific anti-p38 MAPK antibody (anti-p-p38; upper panel). The
stripped nitrocellulose was reblotted with anti-p38 MAPK antibodies
(lower panel).
FIG. 13. Schematic representation of the proposed mechanism
by which ET-1 signals through Pyk2 in mesangial cells. ET-1
induces a rapid mobilization of intracellular free calcium and concom-
itant activation of protein kinase C. Mobilization of free calcium is
required for autophosphorylation of Pyk2 on Tyr-402. However, activa-
tion of protein kinase C also results in Src-dependent tyrosine phospho-
rylation of Pyk2. Autophosphorylation of Pyk2 leads to association with
Src, resulting in further activation of Src tyrosine kinase activity.
Activation of Pyk2 results in the recruitment of unidentified adaptor
protein(s) promoting GTP loading of small GTP-binding proteins re-
sponsible for activation of the p38 MAPK cascade. PLCb, phospholipase
Cb; PIP2, phosphatidylinositol bisphosphate; DAG, sn-1,2-diacylglyc-
erol; IP3, inositol 1,4,5-trisphosphate; PKC, protein kinase C; MKK,
MAP kinase kinase.
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neither by calcium nor by addition of calmodulin suggests that
other proteins that mediate calcium-dependent stimulation of
Pyk2 exist. Multidomain Pyk2-N-interacting receptor (Nir)
proteins are calcium-binding proteins that possess phosphati-
dylinositol transfer activity and were shown to bind to Pyk2 in
vivo and in vitro (60). Of the three Nir proteins thus far de-
scribed (Nir1, Nir2, and Nir3), only Nir2 is ubiquitously ex-
pressed and therefore putatively capable of participating in
Pyk2 signaling in mesangial cells. Nir proteins are mammalian
homologs of Drosophila RDGB (retinal degeneration B) protein,
and expression of the nir2 gene rescues the phenotype of rdgB
mutant flies (61). It is intriguing that RDGB has been proposed
to participate in the pumping of calcium into intracellular
stores (62).
Pyk2 is highly expressed in vascular smooth muscle cells (41,
47), liver epithelial cells (29), cardiac fibroblasts (42), and bone-
resorbing osteoclasts (43). In osteoclasts, Pyk2 colocalizes with
p130cas and may play a role in the formation of the sealing zone
during osteoclast activation (63). Our data, together with find-
ings of other groups, suggest that the role of Pyk2 in coupling
GPCRs with activation of tyrosine-dependent signaling path-
ways is not limited to cells of the nervous system and of hema-
topoietic origin, but represents a generalized mechanism. Since
expression of Pyk2 isoforms generated by alternative RNA
splicing has been reported (64, 65), it is possible that cells
previously reported to lack Pyk2 express alternative
transcripts.
In conclusion, we propose (as summarized in Fig. 13) that p38
MAPK activation in response to ET-1 in mesangial cells occurs
via activation of Pyk2 by a mechanism that is dependent on
calcium mobilization and stimulation of Src family kinases. As
yet, we can only speculate as to how these factors control the
“switching on” of Pyk2 signaling. Further studies will be directed
toward understanding the fine mechanisms of calcium- and Src
kinase-dependent regulation of Pyk2 activity in mesangial cells.
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